Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 39 clinical trials
Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer

RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as cyproterone acetate may stop the adrenal glands from making androgens. Sometimes the tumor may not need treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether giving cyproterone acetate …

endocrine therapy
epinephrine
hormone therapy
gonadorelin
tumor progression
  • 3 views
  • 07 Nov, 2020
  • 1 location
Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer

Cancer Agency (BCCA) since 1998. As part of the treatment, some patients also require hormone therapy for 6 months. This is given as injections of a drug called an LHRH agonist. The LHRH

endocrine therapy
testosterone
gonadorelin
adenocarcinoma
gonadotropin
  • 44 views
  • 07 Nov, 2020
  • 1 location
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate), six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.

  • 1 views
  • 11 Apr, 2021
  • 3 locations
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza …

  • 0 views
  • 14 Feb, 2021
  • 1 location
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is shown in part A.

docetaxel
bone lesions
platelet count
bicalutamide
testosterone
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.

  • 0 views
  • 15 Jun, 2021
  • 99 locations
Prostate Adenocarcinoma TransCutaneous Hormones

RATIONALE: The increasingly prolonged and extended use of androgen deprivation therapy (ADT) in the treatment of prostate cancer, usually achieved through the administration of LHRH agonists

diabetes
testosterone
antiandrogen therapy
gonadorelin
estradiol
  • 291 views
  • 27 Jan, 2021
  • 2 locations
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane) or fulvestrant (Faslodex). Premenopausal women and men may also receive a drug called an LHRH (luteinizing

fulvestrant
endocrine therapy
gnrh
anastrozole
HER2
  • 0 views
  • 24 May, 2021
  • 69 locations
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time 9 months at the time of study entry.

testosterone
recurrent prostate cancer
gonadorelin
immunological adjuvant
serum testosterone
  • 496 views
  • 23 Jan, 2021
  • 68 locations
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)

gonadotropin releasing hormone
endocrine therapy
estradiol
erbb2
immunostimulant
  • 63 views
  • 27 Jan, 2021
  • 67 locations